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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis (AAV) is a group of systemic necrotising vasculitides, 
which often involve small vessels, and which lead to few or no 
immune deposits in affected organs.1 According to clinical 
manifestations and pathological features, AAV is classified 
into three variants: microscopic polyangiitis (MPA), granulo-
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Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a group of systemic necrotising vasculitides, which often in-
volve small vessels, and which lead to few or no immune deposits in affected organs. According to clinical manifestations and 
pathological features, AAV is classified into three variants: microscopic polyangiitis, granulomatosis with polyangiitis (GPA), and 
eosinophilic GPA. The American College of Rheumatology 1990 criteria contributed to the classification of AAV, although cur-
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ticeable advancements in studies on the pathophysiology of AAV and the classification criteria for AAV in Western countries. 
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activity, prognostic factor score, age and specific organ-involvement have been found to be associated with either all-cause mor-
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matosis with polyangiitis (GPA), and eosinophilic GPA (EGPA).2 
GPA and EGPA are identical to what have been called Wegen-
er’s granulomatosis and Churg-Strauss syndrome, although 
GPA and EGPA are more often and widely used.1 MPA mainly 
induces rapid progressive necrotising glomerulonephritis, 
and it occasionally provokes pulmonary capillaritis or alveolar 
haemorrhage.1,2 GPA often involves the upper and lower re-
spiratory tracts, and it also affects the kidneys, leading to 
necrotising glomerulonephritis. EGPA is commonly accom-
panied by allergic features such as asthma and eosinophilia, 
and it frequently involves the lungs and skin.3,4 
Only a few original articles and one review article have re-
ported clinical features and prognosis in Korean patients with 
AAV since 2000.5,6 In this review, we searched articles, not case 
reports, with titles and abstracts including “ANCA,” “vasculi-
tis,” “microscopic polyangiitis,” “granulomatosis with polyan-
giitis (GPA; Wegener’s granulomatosis),” “eosinophilic granu-
lomatosis with polyangiitis (EGPA; Churg-Strauss syndrome),” 
and “KOREA” in PubMed and analysed them. We primarily 
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focused on reclassifying according to new criteria and clinical 
and epidemiological aspects of AAV in the present review. In 
addition, we provided relevant indices through which to esti-
mate the current activity and to predict outcomes in Korean 
patients with AAV.
A glANCe AT The pAThOgeNsIs Of AAV
Antineutrophil cytoplasmic antibodies recognise typical anti-
gens in the cytoplasm of neutrophils, myeloperoxidase (MPO) 
and proteinase 3 (PR3).7 In healthy individuals, ANCAs exhibit 
beneficial homeostatic functions, functioning as “natural AN-
CAs” or “non-pathogenic ANCAs.” Natural ANCAs have lower 
titres, lower avidity, less subclass diversity, and less capability 
to activate neutrophil than pathogenic ANCAs.8 However, 
when this regulation is broken, ANCAs initiate pathogenic au-
toimmunity. Endogenous and exogenous stimuli can convert 
natural ANCAs to pathogenic ANCAs.9 Pathogenic ANCAs 
can provoke autoimmune responses in three ways. The first 
way is by impaired T cell suppression. In AAV patients, 
CD4+CD25+ T cell numbers are increased, while CD4+FoxP3 
T cells are decreased in number. Also, in GPA patients, the ex-
pression of PD-1 on circulating T cells is enhanced, while that 
on renal infiltrated T cells is significantly reduced.10,11 The sec-
ond way is by impaired B cells suppression. CD5+ B cells pro-
ducing IL-10 have regulatory function. In patients with active 
AAV, the number of circulating CD5+ B cells is decreased, and 
normalises after remission.12 The third way is by enhanced B 
cell-stimulation by ANCA-activated neutrophil. ANCA-acti-
vated neutrophil stimulates B cells to produce ANCAs, and it 
releases ligands for B activating factor of TNF family (BAFF), 
leading to plenty of circulating ANCAs and enhanced B cell 
proliferation. In fact, serum BAFF levels are increased during 
active disease in AAV patients and decreased after remis-
sion.13,14
Antineutrophil cytoplasmic antibodies can be generated by 
two assumed mechanisms: 1) Once infectious organism or 
medicines, which are considered perpetrators in the patho-
genesis of AAV, are processed and presented by antigen-pre-
senting cells (APCs), the release of IL-23 is enhanced and it 
accelerates the proliferation of Th17 cells and IL-17 produc-
tion. Increased circulating IL-17 activates macrophages and 
drives them to secrete pro-inflammatory cytokines, resulting 
in priming neutrophils. MPO or PR3 in the cytoplasm of neu-
trophils moves to the surface or are released though lyso-
somes. Secreted MPO or PR3 can be recognised by APCs and 
presented to helper T cells.9,15 Subsequently, helper T cells can 
transfer the antigenic information to B cells, which produce 
anti-MPO or anti-PR3 ANCAs or they may differentiate to T 
effector memory cells, which can participate in granuloma 
formation.15 2) Assuming that antigen 1 is an ANCA antigen 
mimicking antigen, an antibody response against antigen 1 
produces antibody 1. Also, anti-idiotypic responses against 
antibody 1 may produce antibody 2. Antibody 2 can bind 
ANCA antigens and induce cross-reaction of priming and ac-
tivating neutrophils.9 
Aetiologies of AAV increase pro-inflammatory cytokines or 
chemokines, which, in turn, may prime neutrophils. Once neu-
trophils are primed, the expression of neutrophil adhesion mol-
ecules (CD11b) and Fc gamma receptors are remarkably en-
hanced on the surface of neutrophils;16 cytoplasmic ANCA 
antigens moves to the surface or they are released through lyso-
somes (Fig. 1A);15 and the expression of endothelial adhesion 
molecules, such as vascular cell adhesion molecule 1, intercel-
lular adhesion molecule 1 and selectins, is enhanced (Fig. 1B).16 
Circulating ANCA binds to the cell surface or secretory ANCA 
antigens and elicits “ANCA-mediated activation of neutro-
phils” (Fig. 1C). Thereby, the interaction between neutrophils 
and endothelial adhesion molecules is strengthened and in-
duces the migration of neutrophils into adjacent tissues (Fig. 
1D). Also, “ANCA-mediated activation of neutrophil” triggers 
the production of reactive oxygen radicals and the degranula-
tion of neutrophils, leading to bulky inflammation on vessel 
walls as well as in the tissues beyond them (Fig. 1E).16,17 Alter-
native complement pathway can also aggravate “ANCA-medi-
ated activation of neutrophils” by forming a loop of complement 
activating factors to C5a fragment (Fig. 1F).7,15-17 Moreover, re-
cently, the clinical role of neutrophil extracellular traps in asso-
ciation with MPO-ANCA and IL-18 in the pathogenesis of AAV 
has been elucidated.18,19 
ClAssIfICATION CRITeRIA 
The American College of Rheumatology 1990 criteria for the 
classification of AAV (the 1990 ACR criteria) describe EGPA 
and GPA, but not MPA.3,4 The 1990 ACR criteria for EGPA in-
clude history of asthma, eosinophilia (peripheral eosinophil 
>10%), mono- or poly-neuropathy related to systemic vasculi-
tis, migratory non-fixed pulmonary infiltrates, paranasal si-
nusitis, and extravasation of eosinophil on histology. When 
four of the six items are fulfilled, EGPA can be classified.4 Cri-
teria for GPA include nasal or oral inflammation, abnormal 
chest radiography, urinary sediment, and granulomatous in-
flammation on biopsy. When two of the four items are met, 
GPA can be classified.3 The 1990 ACR criteria for EGPA are still 
reliable for use in determining EGPA.1,2 However, those for 
GPA are not specified, and can lead to over-classification, when 
biopsy-proven granuloma is not available. To overcome these 
limitations, the algorithm suggested by the European Medi-
cines Agency in 2007 (the 2007 EMA algorithm) and the Cha-
pel Hill Consensus Conference (CHCC) Nomenclature of 
Vasculitides proposed in 2012 (the 2012 definitions). The 2007 
EMA algorithm has a flowchart in the order of EGPA, GPA, 
MPA, classic polyarteritis nodosa (PAN), and unclassifiable 
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vasculitis, while the 2012 CHCC defines each variant of AAV 
with clinical and histologic features.1,2 The new concepts of PAN, 
based on the 2012 CHCC definitions, are that PAN never pro-
vokes glomerulonephritis and it is rarely associated with ANCA. 
Thus, the presence of glomerulonephritis and any type of 
ANCA can help to exclude PAN.1 
We propose supplanted criteria, which are modifications of 
both the 2007 EMA algorithm and the 2012 CHCC definitions 
as described in Table 1. Before describing the supplemented 
criteria, we disclose that we used the same definitions of GPA 
surrogate markers and renal vasculitis, that were proposed by 
the 2007 EMA algorithm: GPA markers of lower respiratory 
tract involvement include fixed pulmonary infiltrates, nodules 
or cavitations and bronchial stenosis, while those for upper 
respiratory tract include bloody nasal discharge and crusting 
or ulcer, chronic sinusitis, otitis media or mastoiditis, retro-or-
bital mass or inflammation, subglottic stenosis, saddle nose 
deformity or destructive sinonasal disease. Also renal vasculi-
tis includes haematuria [red blood cell (RBC) casts or >10% 
RBC dysmorphism] or haematuria ≥2+ or proteinuria ≥2+ on 
urine stick. When a patient fulfils the 1990 ACR criteria for 
EGPA, a patient is definitely classified as EGPA. When a pa-
tient meets one of the follow three conditions, a patients is 
classified as GPA: 1) granulomatous and vasculitic features on 
histology; 2) vasculitic features without granulomatosis on 
histology and GPA surrogate markers; or 3) GPA surrogate 
markers without histology and the presence of ANCA. When 
a patient exhibits vasculitic features without granulomatosis 
on histology, but no GPA surrogate markers, or a patient has 
renal vasculitis and ANCA under the condition of no histology 
and no GPA surrogate markers, a patient is finally classified as 
MPA. If a patient cannot satisfy the supplemented criteria, a 
patient cannot be classified as AAV. 
ReClAssIfICATION 
PAN is occasionally difficult to be discriminated from AAV. 
PAN had three subgroups including cutaneous, classic, and 
HBV-associated PAN.20 However, based on the 2012 CHCC 
definitions, only classic PAN can be classified as PAN. Cutane-
ous PAN should be reclassified as cutaneous leukocytoclastic 
angiitis or cutaneous arteritis, and HBV-associated PAN 
should be reclassified as HBV-associated vasculitis.1 Park, et 
al.21 applied the supplemented criteria to 32 Korean patients 
with PAN, who were classified according to the 1990 ACR cri-
teria for PAN. Of 32 PAN patients, one patient was reclassified 
as MPA, as that patient exhibited renal vasculitis and had both 
MPO- and PR3-ANCA without GPA surrogate markers. Nine 
of the 32 PAN patients were classified as unclassifiable vascu-
litis, because they exhibited neither histologic and radio-
graphic evidence of PAN nor the fulfilment of the supplement-
ed criteria for AAV. 
EGPA is rarely confused with GPA or MPA, as EGPA exhibits 
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typical allergic components, along with vasculitic features. 
However, patients who are classified as MPA are occasionally 
reclassified as GPA. On the basis of our clinical experiences, a 
29-year-old female patient was classified as MPA due to the 
presence of MPO-ANCA and renal vasculitis without GPA sur-
rogate markers. However, subglottic inflammation and stenosis, 
which was incidentally detected on positron emission tomogra-
phy scan, enabled her to be reclassified as GPA. A 74-year-old 
male patient, who was classified as MPA, could be reclassified 
as GPA based on cavitations and nodules in the right lung. A 
72-year-old female patient with MPA could be also reclassified 
as GPA due to chronic and refractory otitis media. So far, final 
decisions on GPA have often been dependent upon histologic 
finding of typical granuloma. However, in the real clinical set-
ting, the rate of detection of granuloma in patients suspected of 
GPA ranges from 20% to 30%. Thus, we suggest that physicians 
may pay more attention to assessing GPA surrogate markers, 
when classifying patients as AAV, even in patients who were 
previously classified as MPA. 
NeW TRIAls Of ReClAssIfICATION
Recently, a new concept for reclassification of AAV into three 
categories based on the presence of ANCA and its types in-
cluding MPO-ANCA, PR3-ANCA and ANCA negative vasculi-
tis was recently proposed.22 Such efforts have been motivated 
by several needs: First, MPA is classified by the 2007 EMA al-
gorithm and the 2012 CHCC definitions, as MPA does not have 
clear classification criteria, compared to EGPA and GPA.1,2 Sec-
ond, the 1990 ACR criteria for GPA and EGPA are too old to re-
flect currently developed AAVs. Third, neither MPO-ANCA nor 
PR3-ANCA was included in those criteria, despite their clinical 
implications.23 Moreover, recent studies have supported the 
distinct entities among MPO-ANCA, PR3-ANCA, and ANCA 
negative vasculitis.22,24,25 Even in one AAV variant, patients 
having MPO-ANCA can present significantly different clinical 
manifestations from those having PR3-ANCA or no ANCA. 
Furthermore, responses to immunosuppressive drugs can dif-
fer among ANCA types. Yoo, et al.26 applied this classification 
method to 133 Korean patients with AAV (79 MPA, 24 GPA 
and 30 EGPA). Ninety-one patients were reclassified as MPO-
ANCA vasculitis, 21 as PR3-ANCA vasculitis and 21 as ANCA 
negative vasculitis. MPA patients were mainly reclassified as 
MPO-ANCA vasculitis (82.4%), GPA patients as PR3-ANCA 
vasculitis (71.4%), and EGPA patients as ANCA negative vas-
culitis (76.2%). However, ANCA positivity or the type of ANCA 
had no influence on outcomes of AAV. 
The Diagnostic and Classification Criteria for Primary Sys-
temic Vasculitis (DCVAS) and collaborators recently proposed 
the ACR/EULAR (The European League Against Rheuma-
tism) 2017 provisional classification criteria for GPA. These cri-
teria include nine items, of which five items are clinical vari-Ta
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ables and four items are test variables. Different weights are 
assigned to each item as shown in Table 2. The score assigned 
to C-ANCA or PR3-ANCA is the highest among the items. Par-
ticularly, nasal polyps and eosinophilia >10% are major nega-
tive contributors to the diagnosis of GPA. When the sum of 
scores is 5 or greater, patients can be classified as GPA (pre-
sented at 2016 ACR session: New Classification Criteria for 
ANCA-associated Vasculitis: implications for clinical prac-
tice). Yoo, et al.27 applied the 2017 provisional criteria suggest-
ed by DCVAS to 150 Korean patients with AAV. Three patients, 
who had been previously classified as GPA, were reclassified 
as no GPA. All 3 patients had definite histologic evidence of 
granuloma, but they fulfilled no more items. They were not 
reclassified as MPA due to granuloma or EGPA due to no his-
tory of asthma, eosinophilia or eosinophilic extravasation. 
Moreover, the 2017 provisional criteria has several limitations 
that they include no item of kidney involvement for GPA and 
an item of fixed lung infiltrates is excluded. Meanwhile, one 
EGPA patient was reclassified as GPA due to sinonasal con-
gestion (3) and PR3-ANCA positivity (5), despite eosinophilia 
(-3). In this case, PR3-ANCA positivity might be overestimated 
compared to the 1990 ACR criteria or the 2007 EMA algorithm 
modified by the 2012 CHCC definitions. Thus, the weight of 
PR3-ANCA positivity should be readjusted in the near future. 
In addition, 5 MPA patients were reclassified as GPA and PR3-
ANCA also played a major role in the classification of GPA in 2 
patients.27 
AssessmeNT Of DIseAse ACTIVITy 
AND DefINTIONs Of pROgNOsIs
The disease activity of AAV can be mainly assessed by Bir-
mingham vasculitis activity score (BVAS) (or BVAS for GPA)28,29 
and five factor scores [FFS (1996) and FFS (2009)].30 Damage 
derived from AAV can be assessed using vasculitis damage in-
dex (VDI) and combined damage assessment.31 Functions of 
patients AAV are evaluated by generalised methods, such as 
SF-36.32 BVAS is the most widely used to assess vasculitis ac-
tivity in AAV. BVAS is composed of nine major items (plus one 
item of others) including general, cutaneous, mucous mem-
brane/eyes, ear nose throat (ENT), chest (pulmonary), cardio-
vascular, abdominal, renal and nervous system involvements. 
The score assigned to the same sub-items can be different de-
pending on the duration and severity of symptoms, such as per-
sistent and newly developed or worsening.28 The FFS proposed 
in 1996 includes elevated serum creatinine, proteinuria, severe 
gastrointestinal (GI) tract involvement, cardiomyopathy and 
CNS involvement. Meanwhile, the modified version of FFS 
proposed in 2009 consists of age >65 years, insufficient renal 
function, severe GI tract involvement, cardiomyopathy and no 
ENT symptoms.30 Remission is defined as absence of disease 
activity attributable to active disease requiring the maintenance 
of immunosuppressive drugs. Relapse is defined as recurrence 
or new onset of active disease. Refractory disease is defined as 
unchanged or increased disease activity in acute vasculitis af-
ter 4 weeks of treatment or lack of response or chronic and 
persistent disease after over 12 weeks of treatment.33 
pReDICTORs AT DIAgNOsIs Of 
pROgNOsIs 
In terms of MPA, Oh, et al.34 first reported the association vari-
ables or indices at diagnosis and prognosis in Korean patients 
with MPA in 2009. Eighteen MPA patients were reviewed, and 
10 patients had died. The most common cause of death was 
diffuse alveolar haemorrhage. BVAS ≥19, FFS ≥1, age ≥66 
years and diffuse alveolar haemorrhage at diagnosis predicted 
all-cause mortality in MPA patients. Ahn, et al.35 also reported 
the results of the similar study in 55 Korean patients with 
MPA. In this study, instead of FFS and diffuse alveolar haem-
orrhage, cardiomyopathy and interstitial lung disease along 
with BVAS >9 and old age were predictors of all-cause mortal-
ity. In 2017, Oh, et al.36 reviewed the medical records of 90 Ko-
rean patients with MPA, and investigated the association be-
tween initial indices and relapse during the follow-up. They 
insisted that chest (pulmonary) and renal involvement, BVAS 
≥13.5, and FFS (1996) ≥1 at the time of diagnosis were inde-
pendent predictors of relapse of MPA. So far, MPO-ANCA and 
PR3-ANCA have been considered to be associated with mor-
tality and relapse in MPA patients, respectively.37,38 However, 
ANCA positivity has not been proven as a predictor of poor 
prognosis in Korean patients with MPA. 
In terms of GPA, Kim, et al.39 reported concrete data regard-
ing clinicopathologic characteristics of Korean patients with 
GPA. Besides Koran patients with MPA, initial ANCA positivity 
was significantly associated with renal involvement of GPA 
and all-cause mortality during the follow-up. Moreover, pa-
Table 2. The ACR/EULAR 2017 Provisional Classification Criteria for GPA
Items Score
Score for the ACR/EULAR 2017 provisional classification 
criteria for GPA
Sum≥5
Bloody nasal discharge, ulcers, crusting or sinonasal congestion 3
Nasal polyps -4
Hearing loss or reduction 1
Cartilaginous involvement 2
Red or painful eyes 1
C-ANCA or PR3-ANCA 5
Eosinophil count ≥1 (×109/L) -3
Nodule, mass or cavitation on chest imaging 2
Granuloma on biopsy 3
ACR, American College of Rheumatology; EULAR, European League Against 
Rheumatism; GPA, granulomatosis with polyangiitis; C-ANCA, cytoplasmic 
antineutrophil cytoplasmic antibody; PR3-ANCA, proteinase 3-ANCA. 
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tients with ANCA exhibited higher initial BVAS for GPA than 
those without, and PR3-ANCA mainly contributed to the ini-
tial BVAS for GPA. They also compared GPA patients accord-
ing to histologic patterns and granulomatous and vasculitic 
types. Patients with the granulomatous type exhibited young 
age and low frequency of renal involvement, compared to 
those with the vasculitic type. Yoo, et al.40 evaluated the pre-
dictors of refractory disease during the follow-up in Korean 
patients with GPA. The optimal cut-offs of BVAS for GPA, and 
FFS (1996) and FFS (2009) at diagnosis to predict refractory 
disease of GPA were 9.5, 2, and 2 respectively. In Kaplan-Mei-
er survival analysis, initial BVAS ≥9.5, FFS (1996) ≥2, and FFS 
(2009) ≥2 meaningfully predicted cumulative refractory dis-
ease free survival. However, in multivariable Cox hazard 
model, only BVAS at diagnosis ≥9.5 was identified as an inde-
pendent predictor of refractory disease in Korean patients with 
GPA. 
In terms of EGPA, Kim, et al.41 analysed the clinical features 
and prognosis in Korean patients with EGPA. They divided 
EGPA patients according to either ANCA positivity or re-
sponses to treatment and compared organ involvements be-
tween the two groups. Between patients with and without 
ANCA at diagnosis, ANCA-negative patients less frequently 
exhibited renal involvement. Also, older age, diagnosis at ear-
lier stage, less cutaneous involvement, more respiratory in-
volvement, high C-reactive protein (CRP), and more general-
ized symptoms were observed in good responders. Meanwhile, 
in another study, Kim, et al.42 investigated initial variables asso-
ciated with relapse during follow-up in Korean patients with 
EGPA. They first obtained the optimal cut-off of FFS to predict 
relapse of EGPA as 1. When they divided EGPA patients ac-
cording to FFS of 1, relapse was identified more frequently in 
patients with FFS ≥1 than those with FFS<1 (68.8% vs. 7.1%). 
mORTAlITy
In Western countries, 1-year-, 5-year-, and 10-year-cumulative 
patient survival rates have been reported as 82–95%, 74–97%, 
and 89%, respectively.43 In East Asian countries with similar 
ethnicities to Korea, 1-year- and 5-year-cumulative patient 
survival rates were reported at 79.1% and 63.6% in Japan, and 
6-month-cumulative patient survival rate was estimated as 
78.7% in China.44,45 In Korea, there have been three reports on 
survival rate in AAV patients before 2016. The first study re-
ported on all-cause mortality in MPA patients with a rate of 
56%.34 The second study reported that 1-year- and 3-year-cu-
mulative survival rates were 93.9% and 89.2% in MPA pa-
tients.35 The third study reported that 22.2% of GPA patients 
died during follow-up.39 In 2016, Lee, et al.46 investigated long 
term prognosis in 48 Korean patients with renal vasculitis. Six 
patients had no ANCAs. In Kaplan-Meier survival analysis, 
ANCA negativity was a significant predictor of renal survival, 
but not patient survival. However, in the multivariable Cox 
hazards model, ANCA negativity did not affect cumulative re-
nal and patient survivals. In 2018, Mun, et al.47  investigated the 
initial predictors of all-cause mortality in 153 Korean patients 
with AAV. Fourteen patients (9.2%) (7 MPA and 7 GPA patients) 
died during the mean follow-up of 56.9 months. Seven patients 
died of bacterial, viral, or fungal pneumonia, and 3 patients 
died of sepsis. In the remaining patients, cardiac arrest of un-
known aetiology, alveolar haemorrhage, H1N1 influenza and 
biliary infection were causes of mortality. One-year-, 5-year-, 
and 10-year-cumulative patient survival rates were calculated 
as 96.1, 94.8, and 92.8% in patients with AAV. In the Kaplan-
Meier survival analysis, FFS (2009) ≥2, chronic kidney disease 
stage ≥3 or end stage renal disease (ESRD), and diffuse alveo-
lar haemorrhage were associated with all-cause mortality in 
AAV patients. However, in the multivariable Cox hazards mod-
el, only FFS (2009) ≥2 (HR 16.5) and diffuse alveolar haemor-
rhage (HR 3.7) at the time of diagnosis were left as indepen-
dent predictors of all-cause mortality.
seRIOUs INfeCTION
Serious infections that require hospitalisation have been re-
ported to occur in 20% to 60% of patients with AAV. The wide 
variability in serious infection rate may stem from AAV vari-
ants, ethnic and geographical differences, antibiotics-prophy-
laxis and the follow-up duration.48,49 In addition, old age,50 im-
munosuppressive drugs,51-53 reduced renal function,54 and no 
ANCA have been found to be related to serious infections.55 
However, most clinical studies regarding serious infection have 
been conducted in Western countries and only a few observa-
tional studies have been undertaken in Korea. Kim, et al.39 re-
ported 20 of 45 Korean patients with GPA (44.4%) suffered 
from various infections, including pneumonia, bacteraemia, 
septic shock, peritonitis, and so on. Yoo, et al.56 reported retro-
spective data on hospitalised infections in 154 Korean patients 
with AAV. Forty-four of the 154 patients (28.6%) had been ad-
mitted for serious infection. One-year-, 5-year-, and 10-year-
cumulative hospitalised infection free survival rates were 85.1, 
77.9 and 72.7%, respectively. Of 44 patients, there were 56 epi-
sodes of hospitalised infection and the most common aetiol-
ogy was pneumonia (29 episodes), followed by aspergillosis (6 
episodes), biliary infection (4 episodes), and pneumocystis 
jirovecii infection (4 episodes). In the Kaplan-Meier analysis, 
BVAS at diagnosis ≥20.5, FFS (2009) at diagnosis ≥1.5, pulmo-
nary manifestation, renal manifestation, MPO-ANCA (or P-
ANCA) and ANCA positivity were remarkably associated with 
hospitalised infection. However, in the multiple Cox hazards 
model analysis, only BVAS at diagnosis ≥20.5 and pulmonary 
involvement were predictors of serious infection. 
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CANCeRs
So far, various autoimmune diseases with chronic inflamma-
tory burdens have been shown to be associated with an in-
crease in the development of cancers. Among autoimmune 
diseases, rheumatoid arthritis (RA), systemic lupus erythema-
tosus, Sjogren syndrome, systemic sclerosis, and idiopathic 
inflammatory myopathies are well-known to be linked to can-
cer occurrence.57-60 No only autoimmune systemic inflamma-
tion driven by AAV, but also immunosuppressive drugs for 
AAV may impair immune surveillance and recognitions of 
cancer cells or act as direct oncogenic aetiology.61,62 Cancers 
occur more frequently in AAV patients than the general popu-
lation [standardised incidence ratios (SIRs) from 1.6 to 2.4].63-66 
Common cancer types are urinary tract cancer, skin cancer 
and haematological cancers.63-65 The overall SIR of cancer in 
AAV patients, however, tends to be reduced due to more safe 
therapeutic regimens and decreased exposure to both AAV it-
self and oncogenic immunosuppressive drugs.67 Yoo, et al.68 
first provided the incidence and types of cancers in 150 Kore-
an patients with AAV (81 MPA, 38 GPA, and 31 EGPA). Four of 
150 AAV patients (2.7%) had cancers with the mean follow-up 
duration of 50.7 months. Each AAV patients exhibited four dif-
ferent cancers, including gastric cancer, lung cancer, prostate 
cancer, and Non-Hodgkin lymphoma. The gap-time from di-
agnosis of AAV to cancer development was less than 1 year in 
two patients. The overall SIR of cancer in AAV patients was 1.43 
compared to the general Korean population, but it was not sta-
tistically significant. Age at diagnosis of cancer, gender, and AAV 
variants did not influence SIRs. 
INDICes AT DIAgNOsIs fOR ACTIVITy 
AND pROgNOsIs 
We have discovered that initial vasculitis activity, prognostic 
factors, and organ-involvement at diagnosis could be associ-
ated with the prognosis of AAV. Here, three laboratory vari-
ables to estimate the current vasculitis activity, as well as out-
comes of AAV, will be introduced. The advantage of the use 
thereof is that they are currently measured in routine blood 
tests. First, the consumption of neutrophils can increase the 
number of immature granulocytes, which is called a granulo-
cytic shift to the left.69 Delta neutrophil index (DNI) is a leuko-
cyte sub-fraction, which is automatically measured by sub-
tracting the fraction of mature polymorphonuclear leukocytes 
from the sum of MPO-reactive cells.70 DNI has been reported 
to be associated with conditions, in which mature neutrophils 
are consumed, such as sepsis and disseminated intravascular 
coagulation.71 Recently, Yoo, et al.72 suggested a association 
between DNI and either current BVAS or relapse in 97 Korean 
patients with AAV. They indicated that DNI could reflect cur-
rent BVAS and that DNI ≥0.65% could predict a higher rate of 
relapse during follow-up of AAV. Second, RBC distribution 
width (RDW) is a value of heterogeneity in the size of circulat-
ing RBCs. RDW is clinically used to discriminate various types 
of anaemia.73 In the meantime, RDW has been considered to 
be linked to inflammatory burden in systemic rheumatic dis-
eases.74,75 Kim, et al.76 reported that RDW was correlated with 
current vasculitis activity only in GPA patients among 150 Ko-
rean patients with AAV. In the Kaplan-Meier survival analysis, 
RDW ≥15.4% and absence of ENT manifestations were associ-
ated with a higher incidence of refractory disease in GPA. Fur-
thermore, in the multivariable Cox hazards analysis, only 
RDW was an independent predictor of refractory disease of 
GPA during follow-up. Third, mean platelet volume (MPV) is 
a marker to reflect platelet distributions in the peripheral circu-
lation. MPV increases as platelet production increases and de-
creases with reduced production of platelets.77 MPV exhibits a 
biphasic pattern in that MPA mainly increases in low-grade in-
flammation, while it often decreases in high-grade inflamma-
tion.78 Kim, et al.79 elucidated that MPV was independently and 
inversely associated with current BVAS in multivariate linear 
regression analysis in 88 Korean patients with MPA. They also 
provided the optimal cut-off of MPV for predicting severe MPA 
(MPV ≤8.85 fL) and demonstrated that MPV increased along 
with improvement of vasculitis activity. 
In addition, several ratios consisting of two or three labora-
tory variables at diagnosis of AAV have been proposed for as-
sessing vasculitis activity at diagnosis as well as prognosis during 
follow-up. Kim, et al.80 applied systemic immune-inflammation 
index (SII) [SII=platelet count×neutrophil count/lymphocyte 
count] to AAV patients. They elucidated that SII at diagnosis 
≥1573.56 could estimate severe AAV at diagnosis and predict 
the poor outcome in AAV patients. Ahn, et al.81 proved that neu-
trophil to lymphocyte ratio and albumin to globulin ratio might 
be useful for assessing the current activity and relapse in AAV 
patients. Park, et al.82 also provided evidence that platelet to 
lymphocyte ratio might be associated with the current activity 
of AAV. Furthermore, it has been recently reported that albumin 
to globulin ratio was inversely associated with all-cause mortal-
ity in MPA patients, and CRP to serum albumin ratio could be a 
risk factor for all-cause mortality in AAV patients.83,84 On the 
other hands, in the pathogenesis of AAV, primed and activated 
neutrophils release complement-activating factors and they, in 
turn, cleave complement 3 (C3) into C3a and 3Cb.85 Thus, it 
could be assumed that serum C3 level may be negatively corre-
lated with AAV activity. Choi, et al.86 clarified that serum C3 level 
<90 mg/dL was associated with both activity and poor progno-
sis of AAV.
OTheRs
Cardiac function
Cardiovascular manifestations as an item of BVAS consists of 
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loss of pulses, valvular heart disease, pericarditis, ischaemic 
cardiac pain (or ischaemic heart disease), cardiomyopathy 
and congestive heart failure.28,29 Cardiovascular manifesta-
tions occasionally occur in AAV, and its incidence rates differ 
for both AAV variants and ANCA types (5–49%).23 Initial in-
volvement of the heart was reported to be related to poor 
prognosis.30,87 Recently, Ahn, et al.88 reported the results of 
echocardiography performed 3 months before and after diag-
nosis of AAV in 89 Korean patients. They compared echocar-
diographic results in AAV patients with those in age- and gen-
der-matched healthy controls. AAV patients showed lower 
mean left ventricular ejection fraction (LVEF) than controls 
(64.0% vs. 69.1%). They also exhibited left ventricular diastolic 
dysfunction more frequently than controls with a higher 
mean E/E’ ratio (11.7 vs. 8.8). Furthermore, measuring right 
ventricular systolic pressure (RVSP), which can estimate the 
presence of pulmonary arterial hypertension, the authors in-
dicated that MPA and EGPA patients, but not GPA patients, 
showed enhanced RVSP than controls. However, there were 
no significant differences in LVEF, E/E’ ratio and RVSP among 
patients with MPA, GPA and EGPA.88 Physicians should be 
encouraged to perform echocardiography within 3 months 
after diagnosis of AAV. 
Outcome of kidney transplantation 
Renal involvement frequently occurs in AAV patients (90–
100% in MPA, 50–80% in GPA, 31–51% in ANCA positive 
EGPA, and 4–16% in ANCA negative EGPA).23 Pauci-immune 
crescentic and necrotising glomerulonephritis are the typical 
histological findings.89 Renal involvement of AAV may rapidly 
progress to ESRD in up to 40% of patients.90,91 In these cases, 
kidney transplantation may be more valuable than dialysis 
maintenance.92,93 So far, histological features, age, PR3-ANCA 
positivity, and creatinine clearance rate at kidney transplanta-
tion were reported to be poor prognostic factors.94 Recently, 
Park, et al.95 first reported the outcome of kidney transplanta-
tion in 144 Korean patients with AAV. Of 144 AAV patients, 
four AAV patients (3 female patients with MPA and 1 male pa-
tient with EGPA) underwent kidney transplantation, and they 
were followed up for more than 2 years. Time-gap from diag-
nosis of AAV to ESRD ranged from 1 to 48 months and that 
from AAV to kidney transplantation was 2 to 95 months. One 
kidney recipient with MPA underwent renal biopsy three 
times due to renal dysfunction. Renal histology revealed re-
jection rather than relapse of MPA. There was no relapse or 
graft failure in the four Korean kidney recipients with AAV. The 
authors concluded that renal outcomes of kidney transplanta-
tion was good and that kidney transplantation could be rec-
ommended as a safe and efficient therapeutic modality in pa-
tients with ESRD related to AAV.95 
Rheumatoid factor false positive 
Rheumatoid factor (RF) is a typical antibody in RA and it can 
increase the accuracy of the classification as RA.96 However, 
RF can be falsely detected in various medical conditions am-
plifying immunoglobulin G (IgG) production.97 AAV is also a 
medical condition augmenting the production of IgG, partic-
ularly ANCAs. Thus, it can be reasonably speculated that RF 
can be frequently detected in AAV patients. Moon, et al.98 re-
viewed the medical records and laboratory data 128 Korean 
patients without RA at the time of diagnosis of AAV and count-
ed the number of patients with RF. The rate of RF false positiv-
ity was 39.1% in AAV patients. In multivariable analysis, cuta-
neous manifestation was the only independent predictor of 
RF false positivity in EGPA patients, but not in MPA and GPA 
patients. They explained the link between cutaneous manifes-
tation and RF false positivity via three hypotheses: First, com-
bination of RF with cryoglobulin is associated with skin vas-
culitis.99 Second, immune-complex depiction of IgG-RF and 
complement 3 in the dermal-epidermal junction drives der-
matitis.100 Third, IgA-RF immune complex induces silent der-
matitis.101 Also, they explained the link between RF-induced 
dermatitis and EGPA by the potential association between RF 
and eosinophilia, leading to eosinophilic pneumonia.102 How-
ever, RF false positivity did not have an influence on the out-
come of AAV or the development of RA.98 
liver related issues 
Although liver is one of the major organs with plenty of capil-
laries like lungs and kidneys, hepatic involvement of AAV 
might have been underestimated due to non-specific symp-
toms.103 However, AAV can theoretically induce the hepatocel-
lular damages and enhance the potential of liver fibrosis simi-
lar to autoimmune hepatitis and primary biliary cirrhosis.104,105 
For predicting liver fibrosis, aspartate aminotransferase to 
platelet ratio index (APRI) and an index of fibrosis (FIB-4) are 
widely used.106 Lee, et al.107 recently reported that AAV may 
provoke subclinical but significant liver fibrosis at diagnosis 
using APRI and FIB-4, and suggested FFS ≥1 at diagnosis as a 
predictor of liver fibrosis. Furthermore, they also reported that 
resolved HBV infection could influence vasculitis at diagnosis 
and relapse after remission in EGPA patients.108
CONClUsIONs AND fUTURe sTUDIes
So far, there have been noticeable advancement in studies on 
pathophysiology of AAV and the classification criteria for AAV 
in Western countries. However, studies analysing clinical fea-
tures of Korean patients with AAV have only been conducted 
and reported since 2000. Nevertheless, Korean physicians 
have rapidly adapted to world-wide changes, and have ap-
plied new concepts and classification criteria to Korean pa-
tients with AAV. In this review, we found several major features 
in Korean patients with AAV. First, initial vasculitis activity, 
prognostic factor score, age and specific organ-involvement 
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seem to be associated with either all-cause mortality or poor 
disease course. ANCA positivity appears to be related to mor-
tality only in GPA. Second, the overall mortality rate during 
follow-up of AAV has been reported to be 9.2%. Furthermore, 
1-year-, 5-year-, and 10-year-cumulative survival rates were 
reported as 96.1, 94.8, and 92.8% in a considerable number of 
AAV patients. Third, the rate of serious infection was described 
as 28.6% and 1-year, 5-year-, and 10-year-cumulative hospital-
ised infection free survival rates ranged 85.1% to 72.7%. Fourth, 
the overall SIR of cancer in AAV patients appeared to be 1.43, 
compared to the general Korean population. 
Nevertheless, previous studies analysing clinical features 
and prognosis in Korean patients with AAV have several limi-
tations of a retrospective study-design and a small number of 
patients. Furthermore, there is no nation-wide cohort of AAV 
in Korea yet. Thus, a prospective future studies with a larger 
number of patients by establishing a Korean nation-wide co-
hort of AAV patients will provide more valuable epidemiologic 
information and the opportunity to participate in internation-
al clinical trials. 
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